{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:17:04Z","timestamp":1787242624149,"version":"build-2736575974"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T00:00:00Z","timestamp":1650412800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T00:00:00Z","timestamp":1650412800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007326","name":"Diakonhjemmet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To explore the frequency and predictors of flares over 2\u2009years during a treat-to-target strategy with urate-lowering therapy (ULT) in patients with gout.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In the treat-to-target, tight control NOR-Gout study patients started ULT with escalating doses of allopurinol. Flares were recorded over 2\u2009years. Baseline predictors of flares during months 9\u201312 in year 1 and during year 2 were analyzed by multivariable logistic regression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 211 patients included (mean age 56.4\u2009years, disease duration 7.8\u2009years, 95% males), 81% (150\/186) of patients experienced at least one gout flare during the first year and 26% (45\/173) during the second year. The highest frequency of flares in the first year was seen during months 3\u20136 (46.8% of patients).<\/jats:p>\n                    <jats:p>Baseline crystal depositions detected by ultrasound and by dual-energy computed tomography (DECT) were the only variables which predicted flares both during the first period of interest at months 9\u201312 (OR 1.033; 95% CI 1.010\u20131.057, and OR 1.056; 95% CI 1.007\u20131.108) and also in year 2. Baseline subcutaneous tophi (OR 2.42, 95% CI 1.50\u20135.59) and prior use of colchicine at baseline (OR 2.48, 95% CI 1.28-4.79) were independent predictors of flares during months 9\u201312, whereas self-efficacy for pain was a protective predictor (OR 0.98 per unit, 95% CI 0.964\u20130.996).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In patients with gout, flares remain frequent during the first year of a treat-to-target ULT strategy, especially during months 3\u20136, but are much less frequent during year 2. Baseline crystal depositions predict flares over 2\u2009years, supporting ULT early during disease course.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.anzctr.org.au\/Trial\/Registration\/TrialReview.aspx?id=370430\">ACTRN12618001372279<\/jats:ext-link>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13075-022-02772-3","type":"journal-article","created":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T03:02:32Z","timestamp":1650423752000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["One- and 2-year flare rates after treat-to-target and tight-control therapy of gout: results from the NOR-Gout study"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6881-9552","authenticated-orcid":false,"given":"Till","family":"Uhlig","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars F.","family":"Karoliussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe","family":"Sexton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tore K.","family":"Kvien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Espen A.","family":"Haavardsholm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Perez-Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilde Berner","family":"Hammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,20]]},"reference":[{"issue":"4","key":"2772_CR1","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1136\/annrheumdis-2013-204463","volume":"74","author":"CF Kuo","year":"2015","unstructured":"Kuo CF, Grainge MJ, Mallen C, Zhang W, Doherty M. Rising burden of gout in the UK but continuing suboptimal management: a nationwide population study. Ann Rheum Dis. 2015;74(4):661\u20137.","journal-title":"Ann Rheum Dis."},{"issue":"11","key":"2772_CR2","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1136\/annrheumdis-2019-215933","volume":"78","author":"D Bursill","year":"2019","unstructured":"Bursill D, Taylor WJ, Terkeltaub R, Abhishek A, So AK, Vargas-Santos AB, et al. Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions of disease states of gout. Ann Rheum Dis. 2019;78(11):1592\u2013600.","journal-title":"Ann Rheum Dis."},{"key":"2772_CR3","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s41927-019-0075-6","volume":"3","author":"N Teoh","year":"2019","unstructured":"Teoh N, Gamble GD, Horne A, Taylor WJ, Palmano K, Dalbeth N. The challenges of gout flare reporting: mapping flares during a randomized controlled trial. BMC Rheumatol. 2019;3:27.","journal-title":"BMC Rheumatol."},{"issue":"7","key":"2772_CR4","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1136\/annrheumdis-2016-210588","volume":"76","author":"MC Fisher","year":"2017","unstructured":"Fisher MC, Rai SK, Lu N, Zhang Y, Choi HK. The unclosing premature mortality gap in gout: a general population-based study. Ann Rheum Dis. 2017;76(7):1289\u201394.","journal-title":"Ann Rheum Dis."},{"issue":"3","key":"2772_CR5","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1136\/annrheumdis-2017-212063","volume":"77","author":"V Sigurdardottir","year":"2018","unstructured":"Sigurdardottir V, Drivelegka P, Svard A, Jacobsson LTH, Dehlin M. Work disability in gout: a population-based case-control study. Ann Rheum Dis. 2018;77(3):399\u2013404.","journal-title":"Ann Rheum Dis."},{"issue":"1","key":"2772_CR6","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3111\/13696998.2010.540874","volume":"14","author":"NL Edwards","year":"2011","unstructured":"Edwards NL, Sundy JS, Forsythe A, Blume S, Pan F, Becker MA. Work productivity loss due to flares in patients with chronic gout refractory to conventional therapy. J Med Econ. 2011;14(1):10\u20135.","journal-title":"J Med Econ."},{"issue":"6","key":"2772_CR7","first-page":"1381","volume":"34","author":"HR Schumacher","year":"2007","unstructured":"Schumacher HR, Taylor W, Joseph-Ridge N, Perez-Ruiz F, Chen LX, Schlesinger N, et al. Outcome evaluations in gout. J Rheumatol. 2007;34(6):1381\u20135.","journal-title":"J Rheumatol."},{"issue":"5","key":"2772_CR8","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1002\/art.33483","volume":"64","author":"AL Gaffo","year":"2012","unstructured":"Gaffo AL, Schumacher HR, Saag KG, Taylor WJ, Dinnella J, Outman R, et al. Developing a provisional definition of flare in patients with established gout. Arthritis Rheum. 2012;64(5):1508\u201317.","journal-title":"Arthritis Rheum."},{"issue":"3","key":"2772_CR9","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1002\/art.40381","volume":"70","author":"AL Gaffo","year":"2018","unstructured":"Gaffo AL, Dalbeth N, Saag KG, Singh JA, Rahn EJ, Mudano AS, et al. Brief report: validation of a definition of flare in patients with established gout. Arthritis Rheumatol. 2018;70(3):462\u20137.","journal-title":"Arthritis Rheumatol."},{"issue":"1","key":"2772_CR10","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1002\/art.39799","volume":"69","author":"N Dalbeth","year":"2017","unstructured":"Dalbeth N, Choi HK, Terkeltaub R. Review: Gout: a roadmap to approaches for improving global outcomes. Arthritis Rheumatol. 2017;69(1):22\u201334.","journal-title":"Arthritis Rheumatol."},{"issue":"12","key":"2772_CR11","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1002\/art.40233","volume":"69","author":"N Dalbeth","year":"2017","unstructured":"Dalbeth N, Saag KG, Palmer WE, Choi HK, Hunt B, MacDonald PA, et al. Effects of febuxostat in early gout: a randomized, double-blind, placebo-controlled study. Arthritis Rheumatol. 2017;69(12):2386\u201395.","journal-title":"Arthritis Rheumatol."},{"issue":"4","key":"2772_CR12","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1002\/art.10511","volume":"47","author":"F Perez-Ruiz","year":"2002","unstructured":"Perez-Ruiz F, Calabozo M, Pijoan JI, Herrero-Beites AM, Ruibal A. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum. 2002;47(4):356\u201360.","journal-title":"Arthritis Rheum."},{"issue":"1","key":"2772_CR13","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","volume":"76","author":"P Richette","year":"2017","unstructured":"Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castaneda-Sanabria J, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;76(1):29\u201342.","journal-title":"Ann Rheum Dis."},{"issue":"6","key":"2772_CR14","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1002\/art.41247","volume":"72","author":"JD FitzGerald","year":"2020","unstructured":"FitzGerald JD, Dalbeth N, Mikuls T, Brignardello-Petersen R, Guyatt G, Abeles AM, et al. 2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis Rheumatol. 2020;72(6):879\u201395.","journal-title":"Arthritis Rheumatol."},{"issue":"23","key":"2772_CR15","doi-asserted-by":"publisher","first-page":"2450","DOI":"10.1056\/NEJMoa050373","volume":"353","author":"MA Becker","year":"2005","unstructured":"Becker MA, Schumacher HR, Wortmann RL, MacDonald PA, Eustace D, Palo WA, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005;353(23):2450\u201361.","journal-title":"N Engl J Med."},{"issue":"10","key":"2772_CR16","first-page":"CD006077","volume":"10","author":"R Seth","year":"2014","unstructured":"Seth R, Kydd AS, Buchbinder R, Bombardier C, Edwards CJ. Allopurinol for chronic gout. Cochrane Database Syst Rev. 2014;10(10):CD006077.","journal-title":"Cochrane Database Syst Rev."},{"issue":"9","key":"2772_CR17","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1136\/ard.2007.078683","volume":"67","author":"EH Kang","year":"2008","unstructured":"Kang EH, Lee EY, Lee YJ, Song YW, Lee EB. Clinical features and risk factors of postsurgical gout. Ann Rheum Dis. 2008;67(9):1271\u20135.","journal-title":"Ann Rheum Dis."},{"issue":"3","key":"2772_CR18","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1002\/art.20405","volume":"51","author":"A Shoji","year":"2004","unstructured":"Shoji A, Yamanaka H, Kamatani N. A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum. 2004;51(3):321\u20135.","journal-title":"Arthritis Rheum."},{"key":"2772_CR19","doi-asserted-by":"crossref","unstructured":"Uhlig T, Karoliussen LF, Sexton J, Borgen T, Haavardsholm EA, Kvien TK, et al. 12-month results from the real-life observational treat-to-target and tight-control therapy NOR-Gout study: achievements of the urate target levels and predictors of obtaining this target. RMD Open. 2021;7(1)e001628.","DOI":"10.1136\/rmdopen-2021-001628"},{"issue":"10","key":"2772_CR20","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1136\/ard.2006.055269","volume":"65","author":"W Zhang","year":"2006","unstructured":"Zhang W, Doherty M, Bardin T, Pascual E, Barskova V, Conaghan P, et al. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2006;65(10):1312\u201324.","journal-title":"Ann Rheum Dis."},{"issue":"3","key":"2772_CR21","doi-asserted-by":"publisher","first-page":"419","DOI":"10.3899\/jrheum.170911","volume":"45","author":"LK Stamp","year":"2018","unstructured":"Stamp LK, Morillon MB, Taylor WJ, Dalbeth N, Singh JA, Lassere M, et al. Variability in the reporting of serum urate and flares in gout clinical trials: Need for Minimum Reporting Requirements. J Rheumatol. 2018;45(3):419\u201324.","journal-title":"J Rheumatol."},{"issue":"2","key":"2772_CR22","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1002\/art.10993","volume":"49","author":"O Sangha","year":"2003","unstructured":"Sangha O, Stucki G, Liang MH, Fossel AH, Katz JN. The Self-Administered Comorbidity Questionnaire: a new method to assess comorbidity for clinical and health services research. Arthritis Rheum. 2003;49(2):156\u201363.","journal-title":"Arthritis Rheum."},{"issue":"2","key":"2772_CR23","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1002\/art.1780230202","volume":"23","author":"JF Fries","year":"1980","unstructured":"Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum. 1980;23(2):137\u201345.","journal-title":"Arthritis Rheum."},{"key":"2772_CR24","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1080\/00207411.1994.11449283","volume":"23","author":"JE Ware Jr","year":"1995","unstructured":"Ware JE Jr, Gandek B, Group TIP. The SF-36 Health Survey: development and use in mental health research and the IQOLA project. Int J Ment Health. 1995;23:49\u201373.","journal-title":"Int J Ment Health."},{"issue":"1","key":"2772_CR25","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1002\/anr.1780320107","volume":"32","author":"K Lorig","year":"1989","unstructured":"Lorig K, Chastain RL, Ung E, Shoor S, Holman HR. Development and evaluation of a scale to measure perceived self-efficacy in people with arthritis. Arthritis Rheum. 1989;32(1):37\u201344.","journal-title":"Arthritis Rheum."},{"issue":"6","key":"2772_CR26","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/S0022-3999(99)00057-4","volume":"47","author":"R Horne","year":"1999","unstructured":"Horne R, Weinman J. Patients\u2019 beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. J Psychosom Res. 1999;47(6):555\u201367.","journal-title":"J Psychosom Res"},{"issue":"11","key":"2772_CR27","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1136\/annrheumdis-2020-217392","volume":"79","author":"HB Hammer","year":"2020","unstructured":"Hammer HB, Karoliussen L, Terslev L, Haavardsholm EA, Kvien TK, Uhlig T. Ultrasound shows rapid reduction of crystal depositions during a treat-to-target approach in gout patients: 12-month results from the NOR-Gout study. Ann Rheum Dis. 2020;79(11):1500\u20135.","journal-title":"Ann Rheum Dis."},{"issue":"6","key":"2772_CR28","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1002\/acr.22754","volume":"68","author":"S Bayat","year":"2016","unstructured":"Bayat S, Aati O, Rech J, Sapsford M, Cavallaro A, Lell M, et al. Development of a dual-energy computed tomography scoring system for measurement of urate deposition in gout. Arthritis Care Res (Hoboken). 2016;68(6):769\u201375.","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"2772_CR29","doi-asserted-by":"crossref","unstructured":"Uhlig T, Eskild T, Karoliussen LF, Sexton J, Kvien TK, Haavardsholm EA, et al. Two-year reduction of dual-energy CT urate depositions during a treat-to-target strategy in gout in the NOR-Gout longitudinal study. Rheumatology (Oxford). 2022 (In press).","DOI":"10.1093\/rheumatology\/keab533"},{"issue":"3","key":"2772_CR30","doi-asserted-by":"publisher","first-page":"388","DOI":"10.3899\/jrheum.160452","volume":"44","author":"A Shiozawa","year":"2017","unstructured":"Shiozawa A, Szabo SM, Bolzani A, Cheung A, Choi HK. Serum uric acid and the risk of incident and recurrent gout: a systematic review. J Rheumatol. 2017;44(3):388\u201396.","journal-title":"J Rheumatol."},{"issue":"2","key":"2772_CR31","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.semarthrit.2018.02.009","volume":"48","author":"L Stamp","year":"2018","unstructured":"Stamp L, Morillon MB, Taylor WJ, Dalbeth N, Singh JA, Lassere M, et al. Serum urate as surrogate endpoint for flares in people with gout: a systematic review and meta-regression analysis. Semin Arthritis Rheum. 2018;48(2):293\u2013301.","journal-title":"Semin Arthritis Rheum."},{"issue":"7","key":"2772_CR32","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1136\/ard.2007.076232","volume":"67","author":"L Annemans","year":"2008","unstructured":"Annemans L, Spaepen E, Gaskin M, Bonnemaire M, Malier V, Gilbert T, et al. Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000-2005. Ann Rheum Dis. 2008;67(7):960\u20136.","journal-title":"Ann Rheum Dis."},{"issue":"5","key":"2772_CR33","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.55563\/clinexprheumatol\/b7jjnb","volume":"39","author":"BF Mandell","year":"2021","unstructured":"Mandell BF, Fields TR, Edwards NL, Yeo AE, Lipsky PE. Post-hoc analysis of pegloticase pivotal trials in chronic refractory gout: relationship between fluctuations in plasma urate levels and acute flares. Clin Exp Rheumatol. 2021;39(5):1085\u201392.","journal-title":"Clin Exp Rheumatol."},{"issue":"8","key":"2772_CR34","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1007\/s10067-019-04566-6","volume":"38","author":"CA Janssen","year":"2019","unstructured":"Janssen CA, Oude Voshaar MAH, Ten Klooster PM, Vonkeman HE, van de Laar M. Prognostic factors associated with early gout flare recurrence in patients initiating urate-lowering therapy during an acute gout flare. Clin Rheumatol. 2019;38(8):2233\u20139.","journal-title":"Clin Rheumatol."},{"issue":"9","key":"2772_CR35","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1136\/annrheumdis-2012-201795","volume":"72","author":"MA Becker","year":"2013","unstructured":"Becker MA, Baraf HS, Yood RA, Dillon A, V\u00e1zquez-Mellado J, Ottery FD, et al. Long-term safety of pegloticase in chronic gout refractory to conventional treatment. Ann Rheum Dis. 2013;72(9):1469\u201374.","journal-title":"Ann Rheum Dis."},{"issue":"10156","key":"2772_CR36","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1016\/S0140-6736(18)32158-5","volume":"392","author":"M Doherty","year":"2018","unstructured":"Doherty M, Jenkins W, Richardson H, Sarmanova A, Abhishek A, Ashton D, et al. Efficacy and cost-effectiveness of nurse-led care involving education and engagement of patients and a treat-to-target urate-lowering strategy versus usual care for gout: a randomised controlled trial. Lancet. 2018;392(10156):1403\u201312.","journal-title":"Lancet."},{"issue":"4","key":"2772_CR37","doi-asserted-by":"publisher","first-page":"613","DOI":"10.3899\/jrheum.190346","volume":"47","author":"MM Elfishawi","year":"2020","unstructured":"Elfishawi MM, Zleik N, Kvrgic Z, Michet CJ Jr, Crowson CS, Matteson EL, et al. Changes in the presentation of incident gout and the risk of subsequent flares: a population-based study over 20 years. J Rheumatol. 2020;47(4):613\u20138.","journal-title":"J Rheumatol."},{"issue":"4","key":"2772_CR38","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.amjmed.2013.12.019","volume":"127","author":"T Neogi","year":"2014","unstructured":"Neogi T, Chen C, Niu J, Chaisson C, Hunter DJ, Zhang Y. Alcohol quantity and type on risk of recurrent gout attacks: an internet-based case-crossover study. Am J Med. 2014;127(4):311\u20138.","journal-title":"Am J Med."},{"issue":"2","key":"2772_CR39","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1097\/BOR.0b013e3283438e13","volume":"23","author":"JA Singh","year":"2011","unstructured":"Singh JA, Reddy SG, Kundukulam J. Risk factors for gout and prevention: a systematic review of the literature. Curr Opin Rheumatol. 2011;23(2):192\u2013202.","journal-title":"Curr Opin Rheumatol."},{"issue":"3","key":"2772_CR40","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1136\/annrheumdis-2019-216277","volume":"79","author":"K Jatuworapruk","year":"2020","unstructured":"Jatuworapruk K, Grainger R, Dalbeth N, Taylor WJ. Development of a prediction model for inpatient gout flares in people with comorbid gout. Ann Rheum Dis. 2020;79(3):418\u201323.","journal-title":"Ann Rheum Dis."},{"issue":"3","key":"2772_CR41","doi-asserted-by":"publisher","first-page":"558","DOI":"10.3899\/jrheum.131244","volume":"41","author":"N Dalbeth","year":"2014","unstructured":"Dalbeth N, Zhong CS, Grainger R, Khanna D, Khanna PP, Singh JA, et al. Outcome measures in acute gout: a systematic literature review. J Rheumatol. 2014;41(3):558\u201368.","journal-title":"J Rheumatol."}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-022-02772-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-022-02772-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-022-02772-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T13:15:47Z","timestamp":1675343747000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-022-02772-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,20]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2772"],"URL":"https:\/\/doi.org\/10.1186\/s13075-022-02772-3","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,20]]},"assertion":[{"value":"11 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Norwegian Regional Committee for Medical and Health Research Ethics South East (reference number 2015\/990), and the patients gave their written informed consent according to the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr. Uhlig reports personal fees from Gr\u00fcnenthal and Novartis, outside the submitted work.Dres. Karoliussen, Sexton, and Borgen have nothing to disclose. Dr. Kvien reports grants and personal fees from AbbVie, MSD, UCB, Hospira\/Pfizer, Eli-Lilly, grants from BMS, personal fees from Roche, Hikma, Orion, Sanofi, Celltrion, Sandoz, Biogen, Amgen, Egis, Ewopharma, and Mylan, outside the submitted work. Dr. Haavardsholm reports personal fees from Pfizer, UCB, Eli Lilly, Celgene, Janssen-Cilag, AbbVie, and Gilead outside the submitted work. Dr. Perez-Ruiz reports personal fees from Amgen, Biogen, and Galapagos, outside the submitted work, and personal fees from Algorithm, Alnylam, Astellas, Arthriti, Menarini, NMD, and Parexel, related to the topic of gout.Dr. Hammer reports personal fees from AbbVie, Lilly, and Novartis, outside the submitted work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"88"}}